Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684166 | 0.84 | IDO1 (0.40) | IDO1CTSSNOTUMIKBKBKDM4E | |
| SCHEMBL16217347 | 0.83 | KIF11 (0.50) | IDO1CTSSMEN1POLBKMT2A | |
| SCHEMBL17975230 | 0.78 | IDO1 (0.39) | IDO1CTSSXDHMEN1POLB | |
| SCHEMBL1763375 | 0.78 | KIF11 (0.47) | IDO1POLBNOTUMMAOBKDM4E | |
| SCHEMBL25538453 | 0.78 | CYP11B2 (0.42) | IDO1 | |
| SCHEMBL18051409 | 0.77 | NOTUM (0.48) | IDO1CTSSNOTUMIKBKBCYP1A2 | |
| SCHEMBL12096268 | 0.77 | XDH (0.53) | CTSSXDHCTSK | |
| SCHEMBL16186300 | 0.77 | IDO1 (0.33) | IDO1 | |
| SCHEMBL5496649 | 0.77 | IDO1 (0.56) | IDO1MEN1KMT2ANOTUMKMO | |
| SCHEMBL17974802 | 0.76 | IDO1 (0.37) | IDO1CTSSXDHMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100354275-C | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2007-12-12 | — | — | CN | claimed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| EP-4103281-A1 | PIKFYVE KINASE INHIBITORS | Acurastem Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| CN-1906199-A | Diazaindole-dicarbonyl-piperazinyl antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2007-01-31 | — | — | CN | disclosed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549313-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005054247-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | IDO1 2/4885CTSS 1470/4885XDH 1229/4885 |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | IDO1 3172/4885CTSS 3230/4885XDH 4224/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | IDO1 419/4885CTSS 3687/4885XDH 2113/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | IDO1 419/4885CTSS 3687/4885XDH 2113/4885 |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | IDO1 2/4885CTSS 1470/4885XDH 1229/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | IDO1 376/4885CTSS 1014/4885XDH 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.